Phreesia, Inc. (NYSE:PHR) Stock Holdings Lifted by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in shares of Phreesia, Inc. (NYSE:PHR) by 8.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 195,267 shares of the company’s stock after acquiring an additional 14,502 shares during the quarter. Bank of New York Mellon Corp’s holdings in Phreesia were worth $4,913,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of PHR. R Squared Ltd purchased a new position in Phreesia in the 4th quarter worth about $30,000. BankPlus Trust Department purchased a new stake in Phreesia during the fourth quarter valued at about $34,000. Venturi Wealth Management LLC acquired a new position in shares of Phreesia in the fourth quarter worth about $76,000. XTX Topco Ltd purchased a new position in shares of Phreesia in the third quarter worth approximately $247,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Phreesia during the third quarter valued at approximately $316,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Phreesia

In other Phreesia news, CFO Balaji Gandhi sold 3,195 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $26.61, for a total transaction of $85,018.95. Following the completion of the sale, the chief financial officer now directly owns 148,509 shares in the company, valued at $3,951,824.49. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Evan Roberts sold 3,519 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $30.06, for a total value of $105,781.14. Following the sale, the chief operating officer now owns 741,197 shares of the company’s stock, valued at approximately $22,280,381.82. The trade was a 0.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 162,426 shares of company stock worth $4,609,295 over the last three months. Corporate insiders own 5.80% of the company’s stock.

Phreesia Stock Performance

Shares of PHR opened at $27.08 on Tuesday. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -18.42 and a beta of 1.03. The company’s fifty day moving average is $27.32 and its 200-day moving average is $23.99. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53.

Analyst Upgrades and Downgrades

PHR has been the subject of a number of recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Canaccord Genuity Group lifted their price target on Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Citigroup upped their price target on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Robert W. Baird lowered their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, March 13th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $31.33.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.